Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3046% below fair value
$24.66−0.19 (-0.76%)
Close on Nov 13, 2026Market cap $678.53MP/E –Yield –
Fulgent Genetics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Fulgent Genetics's enterprise value was $445.95M on Nov 11, 2026, against $791.85M a year earlier. Over the last 5 years it ranged from $132.73M to $2.80B, with a median of $657.62M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $445.95M | -35.3% |
| 2025 | Dec 31, 2025 | $689.72M | +36.6% |
| 2024 | Dec 31, 2024 | $504.92M | -35.9% |
| 2023 | Dec 29, 2023 | $787.37M | +9.4% |
| 2022 | Dec 30, 2022 | $719.48M | -74.3% |
| 2021 | Dec 31, 2021 | $2.80B | +145.7% |
| 2020 | Dec 31, 2020 | $1.14B | +445.8% |
| 2019 | Dec 31, 2019 | $208.76M | +747.3% |
| 2018 | Dec 31, 2018 | $24.64M | -64.0% |
| 2017 | Dec 29, 2017 | $68.36M | -51.3% |
| 2016 | Dec 30, 2016 | $140.42M | – |
See a number that looks wrong?